News | Avance Clinical Wins Frost & Sullivan “2020 Asia-Pacific CRO Market Leadership Award”

July 8, 2020

The leading Australian CRO for biotechs, Avance Clinical, accepted the prestigious Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award at a global virtual awards ceremony overnight.

Adelaide, Australia – The leading Australian CRO for biotechs, Avance Clinical, accepted the prestigious Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award at a global virtual awards ceremony overnight.

According to Frost & Sullivan:

“The Frost & Sullivan Best Practices awards have identified and honored best-in-class companies that have demonstrated excellence in their respective industries. Award recipients were identified based on in-depth interviews, analysis, and extensive secondary research conducted by Frost & Sullivan analysts and companies are typically studied on their revenues, market share, capabilities, and overall contribution to the industry in order to identify best practices.”

This is the first Frost & Sullivan award for the company which has seen rapid growth in the APAC region over the past year.

Avance Clinical CEO Yvonne Lungershausen commended her team of more than 100 clinical trial specialists throughout Australia and New Zealand.

“We have shown, with our repeat business rate greater than 75%, that our consistent sponsor focussed culture and nimble proactive approach wins every time. This has been recognised by the research team at Frost & Sullivan and the entire Avance Clinical team are very proud.”

“Australia, which has successfully managed the COVID-19 crisis, is open for business for clinical trials. This award further reinforces to the biotech community that this is an early phase specialist destination where they can turn around delayed trials.”

“Avance Clinical are experts in facilitating fast study start up with trials typically approved and initiated in under 6 weeks.”

Avance Clinical is an Australian owned Contract Research Organisation that has been providing high-quality clinical research services fit for global regulatory standards to the local and international drug development industry for 20 years.

Avance specialises in supporting biotech companies with their early phase clinical trials having conducted over 150 early phase (Phase 1 and 2) trials in the past 4 years involving treatment of over 8,300 participants across 95 therapeutic indications.

According to Nidhi Jalali, Analyst Best Practices, Frost & Sullivan:

“Within Asia-Pacific’s highly competitive CRO market, Avance Clinical stands out as a leader in early phase biotech clinical trials. The company offers a highly responsive and proactive service for biotechs wanting rapid and innovative clinical trial solutions, with the highest level of data compliance.

Avance Clinical is a full service CRO with a 20-year track-record.

The company has grown quickly over the past year doubling staff numbers and with plans to further expand in the region. Avance Clinical offers a real size match for biotechs that means better mission understandings and stronger customer service compared to some of the larger CROs. 

Avance’s reputation for high-quality clinical trial outcomes leveraging its scientific and regulatory expertise has attracted an impressive 74% repeat business rate, underscoring the company’s position as a market leader.”

In addition to the impressive COVID-19 management in Australia, a key factor in sponsor demand is the speed, access to high quality sites and attractive cost of running trials in Australia including:

Watch video – how we work https://www.avancecro.com/

Australia’s reputation for FDA compliant scientific and research excellence, its advanced healthcare, and the opportunity to access patients in a less clinical trial competitive environment further reinforces its advantage as a destination for clinical trials.

For more information about the benefits of running your next study with Avance Clinical contact us: https://www.avancecro.com/contact-us/

About the Award

The Frost & Sullivan Best Practices awards have identified and honored best-in-class companies that have demonstrated excellence in their respective industries. Award recipients were identified based on in-depth interviews, analysis, and extensive secondary research conducted by
Frost & Sullivan analysts and companies are typically studied on their revenues, market share, capabilities, and overall contribution to the industry in order to identify best practices.

For the Market Leadership Award, Frost & Sullivan analysts independently elucidated the following key benchmarking criteria:

1. Technology Leverage

2. Customer Purchase Experience

3. Price/Performance Value

4. Growth Strategy Excellence

5. Customer Service Experience

6. Brand Strength

With its strong overall performance, Avance Clinical Pty Ltd has earned the 2020 Asia-Pacific CRO Market Leadership Award. We also recognize that your receipt of this award is the result of many individuals (employees, customers and investors) making daily choices to believe in the organization and contribute in a meaningful way to its future.

About Avance Clinical

Australia’s Avance Clinical has more than 20-years of experience and is now one of Australia’s leading Contract Research Organisations. Avance Clinical facilitates quality drug development by aligning people, skills, and expertise in the pursuit of drug development for a healthier world.

Avance Clinical is committed to providing high-quality clinical research services with its highly-experienced team.

The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field.

Avance Clinical offers high quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialised patient groups. Other benefits include:

  1. The Government R&D grant means up to 43.5% rebate on clinical trial spend
  2. Telehealth pivot during COVID-19 pandemic – speed and continuity
  3. Site Initiation Visit (SIV) and Study Start achieved in 5 – 6 weeks
  4. No IND required for clinical trials
  5. Full GMP material is not mandated for Phase I clinical trials 
  6. Established clinical trial environment with world-class Investigators and sites
  7. Established healthy subject databases and specialised patient populations
  8. Five independent Phase 1 facilities across Australia including hospital-based units for critical care
  9. Major hospitals with world class infrastructures and dedicated Clinical Trial Units with a long track-record in FDA compliant research
  10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies year-round by taking advantage of Australia’s counter-flu and allergy seasons
All Blog Posts